“Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo”. SKIN The Journal of Cutaneous Medicine, vol. 3, Nov. 2019, p. S53, https://doi.org/10.25251/skin.3.supp.53.